Tianjin Ringpu Bio-Technology Co (300119) Fair Value & Analysis
Healthcare · CN · Market cap 7.3B CNY
Fair value as of: Jul 7, 2026
From 26 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from ¥18.96 to ¥24.41 (+28.7%) since Jun 24, 2026. Share price +15.7% over the past month.
A solid business, screening 34% undervalued on our models.
What matters now
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (¥15.12 to ¥30.95) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range ¥10.91 – ¥38.60 · fair‑value band ¥15.12 – ¥30.95 · the ¥18.20 price screens below the ¥24.41 fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Tianjin Ringpu Bio-Technology Co (300119) currently trades at ¥18.20, while our model-based Fair Value estimate is ¥24.41, implying the stock looks roughly 34.1% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Tianjin Ringpu Bio-Technology Co generated revenue of 3.4B CNY at a net margin of 11.5%. Revenue grew 0.5% year over year. It earns a return on equity of 8.3%. Net debt stands at 503M CNY. Fundamentals as of Jul 7, 2026
Our scenario range runs from ¥15.12 (bear case) to ¥30.95 (bull case); at ¥18.20, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 34%, 300119 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥20.16) versus Dividend Discount (¥5.45). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products.
Full company description
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and poultry, waterfowl, livestock, rumination, pets, washing and disinfection, active pharmaceutical ingredients product series. It also offers diagnosis and treatment services, such as epidemic diagnosis and testing, animal drug evaluation, and veterinary socialization. The company was founded in 1998 and is headquartered in Tianjin, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tianjin Ringpu Bio-Technology Co reported revenue of ¥3.4B in FY2025 versus ¥2.0B in FY2021, a compound +14.1%/yr. Reported net income was ¥401M in FY2025, compounding −0.8%/yr from FY2021.
Watch 300119: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Tianjin Ringpu Bio-Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tianjin Ringpu Bio-Technology Co (300119) overvalued or undervalued?
What is the fair value of 300119?
What is the quality score of 300119?
What is the revenue of Tianjin Ringpu Bio-Technology Co (300119)?
What is the net profit margin of 300119?
Does Tianjin Ringpu Bio-Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tianjin Ringpu Bio-Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.